Comorbidity index does not predict outcome in allogeneic myeloablative transplants conditioned with fludarabine/i.v. busulfan (FluBu4)

Bone Marrow Transplantation

Volumn 46, Issue 10, 2011, Pages 1326-1330

  Patel, P ^a   Sweiss, K ^a   Nimmagadda, S ^a   Gao, W ^a   Rondelli, D ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

allogeneic hematopoietic stem cell transplantation; busulfan; comorbidity index; fludarabine; TRM

Indexed keywords

ACICLOVIR; BUSULFAN; COTRIMOXAZOLE; FLUCONAZOLE; FLUDARABINE; METHOTREXATE; PENTAMIDINE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COMORBIDITY; COMORBIDITY INDEX; DONOR; DRUG BLOOD LEVEL; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MALE; MEDICAL PARAMETERS; MORTALITY; MYCOSIS; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; PREDICTION; PRIORITY JOURNAL; RELIABILITY; RETROSPECTIVE STUDY; SCORING SYSTEM; VIRUS INFECTION;

ADOLESCENT; ADULT; BUSULFAN; COMORBIDITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE; YOUNG ADULT;

EID: 80053969303     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.293     Document Type: Article

References (18)

1. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568. (Pubitemid 19092391)
2. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004; 104: 961-968. (Pubitemid 39038014)
3. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)- specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919. (Pubitemid 41510773)
4. Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Chen HY, Mahmud N et al. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 38: 477-482. (Pubitemid 44445352)
5. Beri R, Chunduri S, Sweiss K, Peace DJ, Mactal-Haaf C, Dobogai LC et al. Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. Bone Marrow Transplant 2010; 45: 249-253.
6. Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Quigley J, Chen YH et al. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both? Bone Marrow Transplant 2008; 41: 935-940. (Pubitemid 351850496)
7. Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG et al. Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007; 25: 4246-4254. (Pubitemid 47554249)
8. Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008; 111: 446-452.
9. SorrorML, Giralt S, Sandmaier BM, De Lima M, ShahjahanM, Maloney DG et al. Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007; 110: 4608-4613.
10. Guilfoyle R, Demers A, Bredeson C, Richardson E, Rubinger M, Szwajcer D et al. Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center. Bone Marrow Transplant 2009; 43: 133-139.
11. Majhail NS, Brunstein CG, McAvoy S, DeFor TE, Al- Hazzouri A, Setubal D et al. Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants. Biol Blood Marrow Transplant 2008; 14: 985-992.
12. Pollack SM, Steinberg SM, Odom J, Dean RM, Fowler DH, Bishop MR. Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 223-230.
13. Farina L, Bruno B, Patriarca F, Spina F, Sorasio R, Morelli M et al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia 2009; 23: 1131-1138.
14. Lim ZY, Ingram W, Brand R, Ho A, Kenyon M, Devereux S et al. Impact of pretransplant comorbidities on alemtuzumabbased reduced intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML. Bone Marrow Transplant 2010; 45: 633-639.
15. Kataoka K, Nannya Y, Ueda K, Kumano K, Takahashi T, Kurokawa M. Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study. Bone Marrow Transplant 2010; 45: 513-520.
16. Sorror M, Storer B, Sandmaier BM, Maloney DG, Chauncey TR, Langston A et al. Hematopoietic cell transplantation comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008; 112: 1992-2001. (Pubitemid 351574075)
17. Barba P, Piñana JL, Martino R, Valcárcel D, Amoro's A, Sureda A et al. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut points to determine low, intermediate and high risk groups: the flexible HCT-CI is the best predictor of NRM and OS in a population of patients undergoing allo-RIC. Biol Blood Marrow Transplant 2010; 16: 413-420.
18. Sorror ML, Storer B, Storb RF. Validation of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in single and multiple institutions: limitations and inferences. Biol Blood Marrow Transplant 2009; 15: 757-758.